Judiciary Committee
January 29, 2025
Committee Chair: Sen. Carolyn Bosn (Vice Chair DeBoer presiding for portions) | Bills Heard: 6 | Full Transcript (PDF)
LB316: Ban synthetic cannabinoids derived from hemp
Introduced by: Sen. Senator Kauth | Testimony: 3 proponents, 73 opponents, 0 neutral | Read bill text (PDF)
Senator Kauth's LB316 would ban synthetic cannabinoids like Delta-8, but faces fierce opposition from hemp retailers and skepticism from some senators. The bill would limit THC concentration to 0.3% total weight and require decarboxylation testing, targeting products sold in roughly 300 Nebraska stores. Kauth and Attorney General Hilgers argue these untested products cause psychosis and addiction, citing 10,063 poison control calls nationally since 2021. But opponents—including hemp business owners and a chemistry professor—contend Delta-8 is naturally occurring, legally protected under federal law, and that regulation through LB16 is preferable to an outright ban. The hemp industry argues a ban would eliminate hundreds of jobs and millions in tax revenue while driving consumers to black markets. Sen. DeBoer raised concerns about unintended felony liability for consumers and fiscal impact, while Sen. McKinney questioned whether banning is consistent with how the state treats alcohol and tobacco. No vote was taken.
Committee sentiment: Skeptical: Sen. DeBoer, Sen. McKinney, Sen. Hallstrom Unclear: Sen. Rountree
Sentiment estimated from questions and comments — not stated positions.
LB6: Drug-induced homicide enhancement for fentanyl and other controlled substances
Introduced by: Sen. Senator Bosn | Testimony: 5 proponents, 3 opponents, 0 neutral | Read bill text (PDF)
Senator Bosn's LB6 would enhance penalties for drug dealers whose products cause death, but faces pushback over intent requirements and disparate impact. The bill would increase penalties from 1-50 years to 20 years to life when delivery of fentanyl or other controlled substances results in death or serious bodily injury. Bosn and county prosecutors argue dealers should be accountable for deaths—fentanyl is the leading cause of death for Americans 18-45, and 26 states have passed similar laws. But defense attorneys and a physician testified that the bill lacks an intent element, could criminalize low-level dealers and teenagers who don't know products contain fentanyl, and won't deter use based on historical evidence. Sen. McKinney raised concerns about disproportionate enforcement in communities of color and whether increased penalties actually reduce drug sales. Sen. DeBoer questioned whether someone delivering non-controlled substances unknowingly laced with fentanyl would face felony liability. No vote was taken, but amendments addressing intent and safe harbors were discussed.
Committee sentiment: Supportive: Sen. Hallstrom, Sen. Storm Skeptical: Sen. McKinney, Sen. DeBoer
Sentiment estimated from questions and comments — not stated positions.
LB165: Authorize syringe service programs in Nebraska
Introduced by: Sen. Senator Hunt | Testimony: 10 proponents, 1 opponents, 0 neutral | Read bill text (PDF)
Senator Hunt's LB165 would allow local communities to establish syringe service programs, but DHHS testified in opposition citing recent economic studies. The bill removes state barriers to SSPs while leaving implementation decisions to cities, counties, and villages. Proponents—including harm reduction advocates, physicians, and families who lost loved ones—cited CDC research showing SSPs reduce HIV and hepatitis C transmission by 50% and increase treatment entry 4-5 times. They noted Nebraska's HIV diagnoses jumped 26% (2018-2021) while the US saw a 5% decrease. But Dr. Janousek from DHHS testified that recent economic journal studies show SSPs may increase opioid deaths by 2-3.5% while decreasing HIV by only 1.1%, and that Nebraska has fewer than 10 IV drug use-related HIV cases annually. He argued resources should focus on sexual transmission prevention instead. Sen. DeBoer questioned why DHHS cited economic rather than medical journals, while Sen. Storer raised concerns about oversight and implementation costs. No vote was taken.
Committee sentiment: Supportive: Sen. DeBoer, Sen. McKinney, Sen. Holdcroft Skeptical: Sen. Storer, Sen. Storm
Sentiment estimated from questions and comments — not stated positions.
LB16: Regulate consumable hemp products through Liquor Control Commission
Introduced by: Sen. Senator Cavanaugh | Testimony: 3 proponents, 1 opponents, 1 neutral | Read bill text (PDF)
Senator Cavanaugh's LB16 would regulate consumable hemp through the Liquor Control Commission, but the Attorney General's office testified it would illegally legalize synthetic cannabinoids. The bill would require licensing, age restrictions (21+), labeling, packaging limits, 150-foot school distance, and a 3% excise tax—generating an estimated $3.5-4.3 million annually. Proponents including hemp retailers and the Liquor Control Commission argue regulation is preferable to prohibition and that hemp products are legal under federal and state law. But Joshua Dethlefsen from the AG's office testified that LB16 would legalize synthetic cannabinoids that were never intended to be legal and contain unknown compounds. Sen. Cavanaugh countered that hemp products are currently legal and regulation provides clarity. Sen. Bosn questioned the 150-foot school distance, suggesting 1,000 feet would be more appropriate. Sen. McKinney raised concerns about felony conviction restrictions. No vote was taken, but amendments addressing manufacturer licensing and school distance were discussed.
Committee sentiment: Supportive: Sen. Cavanaugh, Sen. McKinney, Sen. Holdcroft Skeptical: Sen. Bosn, Sen. Rountree
Sentiment estimated from questions and comments — not stated positions.
LB431: Add kratom to Nebraska's controlled substances list
Introduced by: Sen. Senator Lippincott | Testimony: 1 proponents, 26 opponents, 1 neutral | Read bill text (PDF)
Senator Lippincott's LB431 would ban kratom as a controlled substance, but opponents argue regulation through LB230 is preferable and that the real problem is synthetic versions. Lippincott testified that FDA reported 44 kratom deaths in 2018 and Tampa Bay Times reported 587 deaths in Florida over 10 years. He shared a personal story of a young man who became addicted to kratom after using it to get off pain medication. But 26 testifiers opposed the ban, arguing kratom has centuries of safe use, that FDA and DEA rejected bans due to insufficient evidence, and that 13 states regulate rather than ban it. Walker Gallman from the Global Kratom Coalition explained that natural kratom leaf is safe but synthetic 7-hydroxymitragynine is the real problem. Mac Haddow from the American Kratom Association cited a Johns Hopkins study showing 87% of kratom users reported it helped with opioid withdrawal. Sen. Storm questioned whether deaths occurred before synthetic versions appeared, while Sen. Storer asked why kratom isn't prescribed if it's effective. No vote was taken, but the distinction between natural kratom and synthetic 7-hydroxymitragynine emerged as central to the debate.
Committee sentiment: Skeptical: Sen. Storm, Sen. Storer Unclear: Sen. Rountree
Sentiment estimated from questions and comments — not stated positions.
LB230: Kratom Consumer Protection Act—regulate kratom products
Introduced by: Sen. Senator Hallstrom | Testimony: 14 proponents, 2 opponents, 1 neutral | Read bill text (PDF)
Senator Hallstrom's LB230 would regulate kratom products through the Department of Revenue, with 14 testifiers supporting and 2 opposing—mostly over how to handle synthetic 7-hydroxymitragynine. The bill includes age restrictions (21+), labeling requirements, good manufacturing practices compliance, and a product registry with January 1, 2026 implementation. It limits 7-hydroxymitragynine to 2% concentration. Hallstrom argued that 18 states regulate kratom and that new synthetic products warrant consumer protection. Kratom retailers and advocates testified that regulation is preferable to prohibition and that natural kratom has centuries of safe use. But Hannes Zetzsche from Holistic Alternative Recovery Trust testified that the 2% limit is essentially a de facto ban on 7-hydroxymitragynine, which has growing scientific evidence for alleviating opioid addiction. He proposed an amendment allowing higher concentrations with robust regulation, including a 10mg limit per product. Walker Gallman explained that the 2% limit keeps 7-hydroxymitragynine in line with natural levels and prevents dangerous synthetic versions. No vote was taken, but amendments addressing 7-hydroxymitragynine concentration limits were discussed.
Committee sentiment: Supportive: Sen. Hallstrom, Sen. Holdcroft
Sentiment estimated from questions and comments — not stated positions.
Session Notes
This was an exceptionally long hearing lasting over 12 hours, covering six bills with significant public interest. The committee heard testimony on hemp/cannabis regulation (LB316, LB16), drug-induced homicide (LB6), syringe service programs (LB165), and kratom regulation/prohibition (LB230, LB431). Several testifiers appeared multiple times on different bills. The committee combined hearings on LB431 and LB230 for efficiency. Vice Chair DeBoer presided for portions of the hearing due to Chair Bosn's dental procedure. No votes were taken on any bills during the hearing. The committee noted that written position comments submitted for the record were: LB316 (3 proponents, 73 opponents, 0 neutral); LB6 (1 proponent, 2 opponents, 0 neutral); LB165 (36 proponents, 45 opponents, 0 neutral); LB16 (13 proponents, 4 opponents, 0 neutral); LB431 (4 proponents, 26 opponents, 1 neutral); LB230 (14 proponents, 2 opponents, 1 neutral).
Generated by NE Wire Service | Source: Nebraska Legislature Transcribers Office This is an AI-generated summary. Verify all claims against the official transcript.